Skip to content
Trial Eligibility
Menu

Breast Cancer Clinical Trials near Palo Alto, CA

91 studies for Breast Cancer are recruiting at 282 sites within 50 miles of Palo Alto, California, according to ClinicalTrials.gov data processed .

Distances are city-level approximations. See all Breast Cancer trials in the US or all trials near Palo Alto.

Your ZIP is looked up in your browser. We don't receive or store it.

Recruiting now

Breast Cancer studies enrolling near Palo Alto

Showing the 50 nearest of 91 studies.
  1. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    NCT05879926

    • Phase 3
    • Ages 18 to 60 years
    • Sex: Female

    Nearest sites: Palo Alto Medical Foundation Health Care (Palo Alto, CA); Stanford Cancer Institute Palo Alto (Palo Alto, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    32 sites within 50 mi
  2. De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

    NCT04852887

    • Phase 3
    • Ages 50 to 70 years
    • Sex: All

    Nearest sites: Palo Alto Medical Foundation Health Care (Palo Alto, CA); Stanford Cancer Institute Palo Alto (Palo Alto, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    28 sites within 50 mi
  3. Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

    NCT05929768

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Palo Alto Medical Foundation Health Care (Palo Alto, CA); Stanford Cancer Institute Palo Alto (Palo Alto, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    18 sites within 50 mi
  4. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

    NCT06876714

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Stanford Cancer Institute Palo Alto (Palo Alto, CA); Kaiser Permanente-Fremont (Fremont, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    15 sites within 50 mi
  5. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    NCT06058377

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Palo Alto Medical Foundation Health Care (Palo Alto, CA); Palo Alto Medical Foundation-Sunnyvale (Sunnyvale, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    8 sites within 50 mi
  6. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

    NCT06492616

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Stanford Women's Cancer Center (Palo Alto, CA); UCSF Wash Cancer CNTR (Fremont, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 50 mi
  7. Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

    NCT07391774

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Palo Alto Medical Foundation Health Care (Palo Alto, CA); Mills Health Center (San Mateo, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    5 sites within 50 mi
  8. A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

    NCT06790693

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Palo Alto Medical Foundation Research Center (Palo Alto, CA); Palo Alto Medical Foundation Research Center (Sunnyvale, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  9. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

    NCT06982521

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Stanford Women's Cancer Center (Palo Alto, CA); University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (San Francisco, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  10. Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

    NCT05232916

    • Phase 3
    • Ages 18 to 100 years
    • Sex: All

    Nearest sites: Stanford Medicine Cancer Center - Stanford Women's Cancer Center (Palo Alto, CA); University of California San Francisco - Helen Diller Family Comprehensive Cancer Center (San Francisco, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  11. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    NCT05564377

    • Phase 2
    • Ages Any age
    • Sex: All

    Nearest sites: Stanford Cancer Institute Palo Alto (Palo Alto, CA); VA Palo Alto Health Care System (Palo Alto, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  12. EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

    NCT06401421

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Stanford Cancer Institute (Palo Alto, CA); Kaiser Permanente Medical Center (Vallejo, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  13. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    NCT06638307

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Stanford Cancer Center (Palo Alto, CA); UCSF Helen Diller Family Comprehensive Cancer Center (San Francisco, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  14. A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

    NCT04300556

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Stanford Women's Cancer Center (Palo Alto, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  15. A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of the Dayspring Technology for Patients With Breast Cancer Related Lymphedema (BCRL) After Lymphatic Surgery

    NCT04888975

    • Interventional
    • Ages 18 years and older
    • Sex: All

    Nearest site: Dung Nguyen, MD, PharmD (Palo Alto, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  16. Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

    NCT04981119

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest site: Stanford University (Palo Alto, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  17. Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

    NCT06562192

    • Phase 1
    • Ages 18 to 100 years
    • Sex: All

    Nearest site: Stanford University Medical Center (Palo Alto, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  18. A Study of PHST001 in Advanced Solid Tumors

    NCT06840886

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Stanford University School of Medicine (Palo Alto, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  19. ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

    NCT07173751

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest site: Stanford University School of Medicine - Stanford Cancer Institute (SCI) - Stanford Women's Cancer Center (Palo Alto, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  20. A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

    NCT07405801

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Stanford Cancer Institute (Palo Alto, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  21. Post-market Safety Study of LUMISIGHT

    NCT07572162

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest site: Stanford University (Palo Alto, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  22. Post-market Evaluation of LumiSystem: Intraoperative Margin Performance and Clinical Utility (IMPACT) Registry

    NCT07616856

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest site: Stanford University (Palo Alto, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  23. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    NCT03452774

    • Observational
    • Ages Any age
    • Sex: All

    Nearest sites: Massive Bio SYNERGY-AI site (Stanford, CA); Massive Bio SYNERGY-AI site (San Francisco, CA)

    Distance to nearest recruiting site
    ~2 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  24. A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

    NCT04802759

    • Phase 1/2
    • Ages 18 years and older
    • Sex: Female

    Nearest sites: Stanford Cancer Institute (SCI) (Stanford, CA); University of California, San Francisco (UCSF) (San Francisco, CA)

    Distance to nearest recruiting site
    ~2 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  25. Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples

    NCT01034033

    • Observational
    • Ages 18 years and older
    • Sex: Female

    Nearest site: Stanford University School of Medicine (Stanford, CA)

    Distance to nearest recruiting site
    ~2 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  26. Magnetic Resonance Imaging of Breast Cancer

    NCT01035112

    • Interventional
    • Ages 21 years and older
    • Sex: Female
    • Accepts healthy volunteers

    Nearest site: Stanford University School of Medicine (Stanford, CA)

    Distance to nearest recruiting site
    ~2 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  27. Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma

    NCT03909282

    • Interventional
    • Ages 18 years and older
    • Sex: Female

    Nearest site: Stanford University (Stanford, CA)

    Distance to nearest recruiting site
    ~2 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  28. Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

    NCT04119024

    • Phase 1
    • Ages 18 to 75 years
    • Sex: All

    Nearest site: Stanford Cancer Institute (Stanford, CA)

    Distance to nearest recruiting site
    ~2 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  29. Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

    NCT04282044

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Stanford University (Stanford, CA)

    Distance to nearest recruiting site
    ~2 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  30. Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

    NCT04768426

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Stanford University (Stanford, CA)

    Distance to nearest recruiting site
    ~2 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  31. A Study of LY4175408 in Participants With Advanced Cancer

    NCT07046923

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Stanford Medicine Cancer Center (Stanford, CA)

    Distance to nearest recruiting site
    ~2 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  32. A Study of LY4257496 in Participants With Cancer (OMNIRAY)

    NCT07114601

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Stanford University Medical Center (Stanford, CA)

    Distance to nearest recruiting site
    ~2 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  33. A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

    NCT07213791

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Stanford University Medical Center (Stanford, CA)

    Distance to nearest recruiting site
    ~2 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  34. Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

    NCT05827081

    • Phase 3
    • Ages 18 to 100 years
    • Sex: All

    Nearest sites: El Camino Hospital (Mountain View, CA); Palo Alto Medical Foundation (Mountain View, CA)

    Distance to nearest recruiting site
    ~5 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  35. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    NCT06966700

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest site: El Camino Hospital Cancer Center ( Site 0096) (Mountain View, CA)

    Distance to nearest recruiting site
    ~5 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  36. Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

    NCT06418204

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Kaiser Permanente- Marshall Medical Offices (Redwood City, CA); Kaiser Permanente-Fremont (Fremont, CA)

    Distance to nearest recruiting site
    ~6 mi (city-level)
    Recruiting sites
    16 sites within 50 mi
  37. E-Mindfulness Approaches for Living After Breast Cancer

    NCT06748222

    • Phase 3
    • Ages 18 to 50 years
    • Sex: All

    Nearest sites: Kaiser Permanente- Marshall Medical Offices (Redwood City, CA); Kaiser Permanente-Fremont (Fremont, CA)

    Distance to nearest recruiting site
    ~6 mi (city-level)
    Recruiting sites
    16 sites within 50 mi
  38. ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

    NCT05059444

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest site: Redwood City (Redwood City, CA)

    Distance to nearest recruiting site
    ~6 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  39. Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

    NCT05812807

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Kaiser Permanente-Fremont (Fremont, CA); Kaiser Permanente Medical Center - Santa Clara (Santa Clara, CA)

    Distance to nearest recruiting site
    ~11 mi (city-level)
    Recruiting sites
    16 sites within 50 mi
  40. Distance-Based Exercise to Preserve Function and Prevent Disability

    NCT07059884

    • Interventional
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Kaiser Permanente-Fremont (Fremont, CA); Kaiser Permanente Medical Center - Santa Clara (Santa Clara, CA)

    Distance to nearest recruiting site
    ~11 mi (city-level)
    Recruiting sites
    9 sites within 50 mi
  41. Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

    NCT07085767

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Clinical Trial Site (Santa Clara, CA); Clinical Trial Site (Oakland, CA)

    Distance to nearest recruiting site
    ~12 mi (city-level)
    Recruiting sites
    6 sites within 50 mi
  42. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    NCT06393374

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Kaiser Permanente - Santa Clara ( Site 0082) (Santa Clara, CA); Kaiser Permanente - Oakland ( Site 0079) (Oakland, CA)

    Distance to nearest recruiting site
    ~12 mi (city-level)
    Recruiting sites
    5 sites within 50 mi
  43. The PREDICT Registry:

    NCT03448926

    • Observational
    • Ages 30 to 85 years
    • Sex: Female

    Nearest site: Sutter Health (San Mateo, CA)

    Distance to nearest recruiting site
    ~13 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  44. Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

    NCT05297734

    • Interventional
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Santa Clara Valley Medical Center (Fruitdale, CA); Kaiser Foundation Research Institute (San Francisco, CA)

    Distance to nearest recruiting site
    ~15 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  45. The Vanguard Study: Testing a New Way to Screen for Cancer

    NCT06995898

    • Interventional
    • Ages 45 to 75 years
    • Sex: All
    • Accepts healthy volunteers

    Nearest site: Kaiser Permanente-Division of Research (Pleasanton, CA)

    Distance to nearest recruiting site
    ~21 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  46. S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

    NCT03723928

    • Interventional
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Epic Care-Dublin (Dublin, CA); Bay Area Tumor Institute (Oakland, CA)

    Distance to nearest recruiting site
    ~21 mi (city-level)
    Recruiting sites
    6 sites within 50 mi
  47. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

    NCT05633654

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: City of Hope (Duarte) (San Francisco, CA); UCSF Medical Center (San Francisco, CA)

    Distance to nearest recruiting site
    ~28 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  48. Patient Care Outreach, Navigation, Technology and Support 2.0

    NCT06648278

    • Interventional
    • Ages 18 years and older
    • Sex: All

    Nearest sites: University of California, San Francisco (San Francisco, CA); Zuckerberg San Francisco General Hospital (San Francisco, CA)

    Distance to nearest recruiting site
    ~28 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  49. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    NCT01042379

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: University of California San Francisco (UCSF) (San Francisco, CA)

    Distance to nearest recruiting site
    ~28 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  50. Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

    NCT02620852

    • Interventional
    • Ages 30 to 74 years
    • Sex: Female
    • Accepts healthy volunteers

    Nearest site: University of California San Francisco (San Francisco, CA)

    Distance to nearest recruiting site
    ~28 mi (city-level)
    Recruiting sites
    1 site within 50 mi

FAQ

Common questions

What is a clinical trial?
A clinical trial is a research study in people that tests a medical, surgical or behavioral intervention, such as an investigational drug or device. Observational studies are also listed: they collect information without assigning a treatment. Read how clinical trials work.
Is there compensation for joining a Breast Cancer clinical trial?
Compensation for time and travel may be available, but it varies by study and some studies offer none. The amount and schedule are reviewed by an ethics board and described in the consent form. See compensation in clinical trials.
How do I check if I'm eligible?
Each study lists age, sex and other inclusion and exclusion criteria on its ClinicalTrials.gov record. Only the study team can confirm eligibility, usually through a screening call or visit. Talk with your own doctor before joining any study.

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.